Company news

Jointown Pharmaceutical Group Co., Ltd. news in 2026

Jointown Pharmaceutical Group Co., Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Announcement on Subsidiary's Drug Passing Generic Drug Consistency Evaluation

May 26, 2026

Announcement on Resolutions of the 2025 Annual General Meeting

May 21, 2026

Indicative Announcement on Convening the 2025 Annual General Meeting

May 14, 2026

Announcement on Recognition of Subsidiary as High-tech Enterprise

May 12, 2026

Announcement on Subsidiary's Passing GMP Compliance Inspection for Drugs

May 6, 2026

Announcement on Holding Subsidiary Certified as High-tech Enterprise

April 29, 2026

Report for Q1 2026

April 27, 2026

Announcement on Results of Issuing Phase II Ultra-Short-Term Financing Bonds of 2026

April 23, 2026

Announcement on the Subsidiary Receiving the "Acceptance Notice" from the National Medical Products Administration for the Market Application of Azelastine Hydrochloride Nasal Spray

April 21, 2026

Announcement on Temporary Idle Funds’ Investment Management Arrangements for Q1 2026

April 8, 2026

Announcement on Receipt of the "Notice of Registration Acceptance" from the National Association of Financial Market Institutional Investors

April 2, 2026

Announcement on Obtaining Medical Device Registration Certificate by Holding Subsidiary

March 24, 2026

Announcement on the Results of Issuance of the 2026 Phase II Science and Technology Innovation Bonds

March 11, 2026

Announcement on Advance Release and Pledge of Shares by the Controlling Shareholder and Its Persons Acting in Concert

February 10, 2026

Announcement on the Subsidiary Receiving the "Acceptance Notice" from the National Medical Products Administration for the Market Application of Betahistine Hydrochloride Tablets

February 6, 2026

Announcement on Completion of Industrial and Commercial Change Registration and Filing of Articles of Association

January 22, 2026

Announcement on the Results of Issuance of the 2026 Phase I Science and Technology Innovation Bonds

January 21, 2026

Announcement on Entrusted Financial Management in Q4 2025

January 16, 2026

Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026

January 7, 2026

Announcement on Obtaining Drug Registration Certificate for Bupivacaine Hydrochloride Injection

January 6, 2026

Announcement on Provision of Online Voting Reminder Service for General Meeting

January 4, 2026

← Newer news releases